Pharmafile Logo

Infographic: RA Perceptions

HCPs predict the future of the biologics market

Findings from a recent survey of physicians across Europe has revealed that, despite stiff competition from newer biologics, biosimilars and pipeline agents, physicians expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time. Nevertheless, the anti-TNF segment is predicted to experience a strong downturn with a 19% loss in share in the same period.

Download our RA Perceptions: Predicting the future of the European market infographic now »

RA Perceptions is a market research study which is carried out every month amongst a panel of 200 physicians across five European countries (France, Germany, Italy, Spain and the UK) and asks physicians about current and future perceptions of the RA market. These findings are from the June survey. RA Perceptions is a component of a larger ongoing patient tracking study called Therapy Watch RA, conducted by global healthcare market research specialist Research Partnership. An infographic highlights the key findings from the study.

Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market with 15% growth over the next 3 years.

Biosimilars (the approved follow-on products to innovator biologics) will benefit from the greatest gains. Physicians predict a four-fold increase in their use of Hospira’s Inflectra and Celltrion’s Remsima. Despite heavy discounting of some biosimilars in certain markets such as France, the overall market share for these infliximab biosimilars is projected to remain relatively small. Less than 25% of physicians currently report prescribing biosimilars.

Overall, physicians’ awareness of pipeline agents in RA is low. The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative for patients who fail to respond adequately or are intolerant to traditional disease modifying treatments. Of the physicians who were familiar with these agents, 89% said they would prescribe Otezla and 83% stated they would prescribe Xeljanz, in the next 3 years.

The RA biologics market is expected to undergo significant changes in the next few years as newer entrants compete with established brands and biosimilars become increasingly accepted for use as cheaper alternatives to the branded biologics.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

20 questions: Round 6

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month we asked our employees about office life in Singapore.Watch the video: https://www.researchpartnership.com/news/2017/09/20-questions-round-6/

Ageing Asia: What does this mean for the future of healthcare?

Over the last 30 years, Asia’s economic growth has resulted in improved education and healthcare across a broad base of the population. This has contributed to declining fertility and increasing...

Punching above your weight: Combining behavioural and attitudinal data to strengthen segmentations

Segmentation solutions in healthcare are experiencing a welcome comeback. But there appear to be two camps emerging - one camp are proponents of the 'behavioural' segmentation based on secondary sales,...

Qualitative segmentation validation study with backroom brainstorm exercises

Our client had an oncology product in development for the treatment of prostate cancer. The company wanted to conduct research to inform future planning, list development, advisory board creation, and...

PMRC EU, Düsseldorf 2017

We are delighted to be exhibiting and presenting a paper at the Pharmaceutical Market Research Conference 24-25 October in Düsseldorf, GermanyDirector, Anne Cunningham, and Associate Director, Nicky Barclay-Prout, are representing...

Device Attribute Testing

Our client wanted to determine the optimal new blood glucose monitoring device – one that would best retain their current customers and also attract new ones.  They also wanted to...

Research Partnership welcomes 20 new Graduates

This year we are celebrating 20 years in business and as part of our continued growth, we are delighted to announce a new intake of 17 Research Analysts and 3...

Corporate Equity Survey

Our client’s senior management wanted to assess its company’s image amongst their key HCP stakeholders. The client wanted to measure familiarity and perceptions of the company versus its competitors, particularly...

Webcast: Capturing the “moments-of-truth” using online communities and bulletin boards

MROCs and bulletin boards are growing in popularity because they offer specific benefits over or alongside more traditional methodologies – providing the opportunity to create a panel of geographically disperse...

Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017

Living with Ulcerative Colitis (UC) is a study conducted amongst 110 adult UC patients in the US. The study employs a mixed quantitative/qualitative methodology and is available to purchase alongside...